The promise for cell and gene therapies (CGTs) to revolutionize cancer therapy is immense, yet unlocking their full potential to treat more diseases and improve patient access will depend on the selection of donors who can provide high-quality cells and tissues. By addressing the challenges of program-specific donor selection and ensuring that the apheresis material […]